Avalo Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AVTX Nasdaq 2834 www.avalotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avalo Therapeutics, Inc.

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates - Aug 6th, 2026 5:00 am
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference - Jul 22nd, 2026 5:00 am
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum - Jul 7th, 2026 5:00 am
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed - Jun 29th, 2026 7:07 pm
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes - Jun 26th, 2026 5:00 am
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026 - Jun 23rd, 2026 9:36 am
Avalo Therapeutics Appoints Ron Philip to Board of Directors - Jun 23rd, 2026 5:00 am
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody - Jun 16th, 2026 5:00 am
Sector Update: Healthcare Stocks Softer Late Afternoon - Jun 12th, 2026 1:40 pm
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - May 22nd, 2026 2:01 pm
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates - May 13th, 2026 5:00 am
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout - May 6th, 2026 2:07 pm
Avalo shares spike on skin drug data; BioNTech to cut staff - May 6th, 2026 4:30 am
Avalo Therapeutics Announces Pricing of $375 Million Public Offering - May 5th, 2026 9:33 pm
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - May 5th, 2026 2:05 pm
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa - May 5th, 2026 2:01 pm
Avalo Therapeutics Purchases Optional Milestone Buyout - Apr 28th, 2026 5:00 am
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Apr 6th, 2026 9:10 am
Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans - Apr 6th, 2026 6:49 am